Tradestie Institutional Equity Comparison Engine

ZBIO vs UPB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ZBIO Overall Edge

ZBIO Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zenas BioPharma, Inc. Common Stock (ZBIO) driven by superior Momentum & Technical, Options & Structure while UPB counters with relative strength in Growth & Margin. Fundamentally, ZBIO trades at N/M Forward P/E with -2747.5% operating margin (-100.0% YoY revenue) versus UPB at N/M Forward P/E and -6116.0% operating margin (-42.2% YoY). In options structure, ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against UPB sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ZBIO N/M vs UPB N/M Fwd P/E
Growth & Margin Winner UPB
Op Margin -2747.5% vs -6116.0% ยท YoY -100.0% vs -42.2%
Momentum & Technical Winner ZBIO
1Y -21.7% vs -90.8% ยท 52W Pos 46% vs 0%
Options & Structure Winner ZBIO
CONSOLIDATION (13th %ile IV) vs BREAKDOWN (17th %ile IV)
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
UPB NASDAQ
Upstream Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.15
-22.66% 1D
Market Cap $152.4M
1M Return -22.1%
1Y Return -90.79%
Forward P/E N/M
Unified AI Score
43.6 / 100 HOLD
Tech 25.0 Fund 52.0 Flow 66.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ZBIO -21.68% UPB -90.79% Spread: +69.11 pp (ZBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ZBIO Revenue UPB Revenue ZBIO Op. Margin UPB Op. Margin Margin Edge
FY2023 $50M $0M -74.3% -1685.5% ZBIO
FY2024 $10M $0M -3277.8% -3281.2% ZBIO
FY2025 $10M $0M -3830.6% -5618.8% ZBIO

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ZBIO (5) vs UPB (2)
Institutional Metric ZBIO UPB Criterion Row Winner
Market Capitalization Scale $1.9B $152.4M Larger Scale ZBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -100.0% -42.2% Higher Growth UPB
Operating Margin (TTM) Profitability -2747.5% -6116.0% Higher Margin ZBIO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -265.1% -53.5% Higher ROE UPB
52-Week Range Position Momentum 46% ($14โ€“$45) 0% ($2โ€“$34) Stronger Trend ZBIO
Beta / 30D Volatility Risk Regime 1.16ฮฒ ยท 59% Vol 1.70ฮฒ ยท 120% Vol Lower Realized Risk ZBIO
Unified Institutional Score Composite Signal 49.4 / 100 (HOLD) 43.6 / 100 (HOLD) Higher Composite ZBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ZBIO vs UPB Buy Guide
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
UPB BREAKDOWN
152d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live UPB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ZBIO nor UPB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.